Key result
M2-AABs are detected in 40% of DCM patients and linked to idiopathic AF.
Why the study?
The clinical significance of M2-muscarinic acetylcholine receptor autoantibodies in patients with dilated cardiomyopathy needed to be characterised.
Are M2-muscarinic acetylcholine receptor autoantibodies associated with the development of atrial fibrillation in patients with dilated cardiomyopathy?
Population
104 patients with DCM, 104 age-matched idiopathic Af patients, and 104 healthy controls
Comparison
M2-AAB positive vs negative status across DCM, idiopathic Af, and healthy control cohorts
Design
Age-matched case-control study
Authors
Loading...
M2-AAB testing in DCM remains investigational; leaves open their value as biomarkers or therapeutic targets.
Case-Control (n=312)
Are M2-muscarinic acetylcholine receptor autoantibodies associated with the development of atrial fibrillation in patients with dilated cardiomyopathy?
Absolute Event Rate: 40% vs 8%
M2-muscarinic acetylcholine receptor autoantibodies are prevalent in patients with dilated cardiomyopathy and idiopathic atrial fibrillation, and may play a mechanistic role in the development of atrial fibrillation.
Akiyasu Baba (2004) conducted a case-control in Dilated cardiomyopathy and idiopathic atrial fibrillation (n=312). M2-muscarinic acetylcholine receptor autoantibodies (M2-AAB) vs. Healthy controls was evaluated on Detection of M2-AAB using whole sera. M2-muscarinic acetylcholine receptor autoantibodies were detected in 40% of patients with dilated cardiomyopathy and 23% with idiopathic atrial fibrillation, compared to 8% of healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: